% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Tomsitz:300103,
      author       = {D. Tomsitz and E. Livingstone$^*$ and C. Loquai and M.
                      Kaatz and U. Leiter and B. Schilling and P. Terheyden and J.
                      Hassel and M. Sachse and J. Ulrich and E. Dippel and F.
                      Meiss and C. Pföhler and A. Kreuter and R. Herbst and M.
                      Weichenthal and L. Zimmer$^*$ and F. Meier and R.
                      Rauschenberg and P. Mohr and F. Brunnert and I. von
                      Wasielewski and R. Gutzmer and D. Schadendorf$^*$ and C.
                      Berking and S. Ugurel$^*$ and L. Heinzerling},
      title        = {{E}arly termination does not negatively impact the outcome
                      of adjuvant immunotherapy in melanoma.},
      journal      = {Journal of the European Academy of Dermatology and
                      Venereology},
      volume       = {nn},
      issn         = {0926-9959},
      address      = {Oxford [u.a.]},
      publisher    = {Wiley-Blackwell},
      reportid     = {DKFZ-2025-00603},
      pages        = {nn},
      year         = {2025},
      note         = {epub},
      abstract     = {Adjuvant treatment with anti-PD1 antibodies has been shown
                      to effectively reduce the risk of recurrence in patients
                      with resected metastatic melanoma. Whether a full 12-month
                      duration of treatment is needed to achieve full clinical
                      benefit is not known. This study investigated the survival
                      outcome depending on the duration of adjuvant anti-PD1
                      therapy.From the prospective multicentre real-world skin
                      cancer registry ADOREG data of 620 patients who finished
                      adjuvant treatment with nivolumab or pembrolizumab for
                      AJCCv8 stage III/IV resected melanoma was analyzed.
                      Recurrence-free survival (RFS) and overall survival (OS)
                      were compared between patients with regular treatment
                      duration (52 ± 4 weeks; n = 229) and no disease recurrence
                      during therapy (A1) and patients with a premature end of
                      treatment (<48 weeks; n = 214, B). Patients with disease
                      recurrence during adjuvant treatment were included in cohort
                      A2.The median duration of follow-up was 26.0 months
                      [interquartile range (IQR) 18.0-34.0] in group A1 [median
                      treatment duration 51.3 weeks (IQR 50.0-52.1) and 19.0
                      months (IQR 13.0-29.0)] in group B [median treatment
                      duration 22.2 weeks (IQR 10.0-34.8)]. Reasons for early
                      discontinuation were treatment-related side effects in
                      $45.3\%$ (n = 97) and other reasons than toxicity in
                      $54.7\%$ (n = 117). The 2-year rate of RFS was $72.4\%$
                      $(95\%$ CI, 68.5-76.3) for patients in group B and $51.5\%$
                      $(95\%$ CI, 48.8-54.2) in patients with regular and intended
                      regular treatment duration (A1 plus A2). When analysing the
                      patients who did not relapse during adjuvant treatment (A1),
                      there was a significantly higher RFS rate of $84.1\%$
                      $(95\%$ CI, 81.5-86.7). When only assessing patients with a
                      recurrence after more than 12 months after initiation of
                      therapy, there was a trend towards better RFS in patients
                      with regular treatment duration.In patients with resected
                      metastatic melanoma, shorter treatment duration with
                      anti-PD1 antibodies is not associated with a worse outcome.},
      cin          = {ED01},
      ddc          = {610},
      cid          = {I:(DE-He78)ED01-20160331},
      pnm          = {899 - ohne Topic (POF4-899)},
      pid          = {G:(DE-HGF)POF4-899},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:40119686},
      doi          = {10.1111/jdv.20650},
      url          = {https://inrepo02.dkfz.de/record/300103},
}